Augmedix (Nasdaq: AUGX), a healthcare technology company that
delivers industry-leading, ambient medical documentation and data
solutions, announced today that it has reached agreements in
principle for strategic collaborations with three innovative
digital health companies: Myndshft, Ellipsis Health, and The
Sullivan Group. The goal of these partnerships is to enhance the
value delivered to health systems by forging an open network of
digital health solutions that will integrate into Augmedix’s
technology through application programming interfaces (APIs),
structured data feeds, and Augmedix’s bi-directional communication
channel into the point of care.
“Partnering with these healthcare innovators
represents our commitment to drive transformation through open
collaborations and integrations,” said Ian Shakil, Founder,
Director, and Chief Strategy Officer of Augmedix. “‘The whole is
greater than the sum of its parts’ absolutely rings true here. By
bringing Augmedix’s platform and our partners’ technologies
together, we expect to magnify their impact, further driving our
joint missions to tackle the full spectrum of administrative
burdens that clinicians face while improving clinician and patient
experiences.”
Myndshft, a provider of automated prior
authorization software, and Augmedix will work together to take
strategic steps to streamline automated, end-to-end documentation.
Through this partnership, once Augmedix transfers the medical note
to the electronic health record (EHR), Myndshft dynamically
references clinicians’ medical documentation, patients’ health and
benefits information, and payers’ plans and policies to automate
prior authorization submissions on behalf of Augmedix and Myndshft
customers. This process allows information such as authorizations,
denials, appeals, documentation requests, and status monitoring to
be populated back into the EHR, ensuring that the combined services
address administrative challenges while offering seamless scaling,
integration, and support options.
Ellipsis Health, the market leader in
AI-generated vocal biomarker technology for the identification and
monitoring of mental health conditions at scale, intends to work
with Augmedix to better serve clinicians and patients in need of
behavioral healthcare services. Augmedix and Ellipsis Health expect
to be able to automate medical documentation, mental health
screenings, social determinants of health (SDOH) screenings, and
topic analysis to help to identify issues earlier and triage
patients to the appropriate care. Augmedix plans to integrate the
Ellipsis Health API into its platform so that alongside ambient
medical documentation, clinicians will receive patients’ anxiety
and depression severity scores during clinical visits. This will
allow Augmedix and Ellipsis Health to help improve patient
experiences and outcomes.
The Sullivan Group, a leading authority in
patient safety and medical error reduction, is partnering with
Augmedix to advance this mission. Together, Augmedix and The
Sullivan Group plan to offer high-quality, trusted solutions that
integrate medical documentation with a reduction in clinicians’
exposure to diagnosis-related errors through the Clinical Decision
Support System (CDSS). Diagnosis-related errors are the highest
cost driver of malpractice claims in emergency medicine. The
partnership will sit at the heart of helping to solve for
documentation burden, clinician burnout, and patient safety,
especially among emergency departments and ambulatory clinics.
The Augmedix platform harnesses automatic speech
recognition, natural language processing, including large language
models, and structured data sets. It digitizes the natural
conversation between a clinician and patient, extracts the
necessary medical information and then converts the information
into comprehensive medical notes and structured data in real time.
The medical notes are then transferred into the EHR.
These partnerships will expand the benefits of
Augmedix’s platform by incorporating prior authorization, clinical
decision support, and a system designed to reduce clinician
exposure to diagnosis-related medical errors. They will also enable
Augmedix to further leverage the wealth of structured data created
by its platform and will serve to enhance health system ROI and
patient outcomes. The parties have agreed in principle on a
strategic partnership pending finalization of a definitive
agreement.
For more information, visit
https://augmedix.com/partnerships-and-integrations/.
About Augmedix
Augmedix (Nasdaq: AUGX) delivers
industry-leading, ambient medical documentation and data solutions
to healthcare systems, physician practices, hospitals, and
telemedicine practitioners.
Augmedix is on a mission to help clinicians and
patients form a human connection by seamlessly integrating our
technology at the point of care. Augmedix’s proprietary platform
digitizes natural clinician-patient conversations, which are
converted into comprehensive medical notes and structured data in
real time. The company’s platform uses automatic speech recognition
and natural language processing, including large language models,
to generate accurate and timely medical notes that are transferred
into the EHR.
Augmedix’s products relieve clinicians of
administrative burden, in turn, reducing burnout, increasing
clinician efficiency and improving patient access. Through
Augmedix’s proprietary platform and bi-directional communication
channel, Augmedix is ideally suited to serve as the vehicle for
change at the point of care.
Augmedix is headquartered in San Francisco, CA,
with offices around the world. To learn more, visit
www.augmedix.com.
Contact Information
Investors:Matt Chesler, CFAFNK IR646-809-2183augx@fnkir.com
investors@augmedix.com
Media:Kaila GrafemanAugmedixpr@augmedix.com
Forward-Looking Statements
This press release contains “forward-looking
statements” that involve a number of risks and uncertainties. Words
such as “believes,” “may,” “will,” “estimates,” “potential,”
“continues,” “anticipates,” “intends,” “expects,” “could,” “would,”
“projects,” “plans,” “targets,” “excited,” “optimistic,” and
variations of such words and similar expressions are intended to
identify forward-looking statements. Such forward-looking
statements include, without limitation, statements regarding the
expected benefits of the planned partnerships with Myndshft,
Ellipsis Health and The Sullivan Group, including improving patient
experiences and outcomes; statements regarding the expected
partnerships with Augmedix furthering to enhance healthcare
enterprise efficiency and patient outcomes through integrations and
offerings leveraging high-quality structured data, ambient AI, and
Augmedix’s bi-directional communication channel into the point of
care; statements regarding the enhanced value delivered to health
systems by forging an open network of digital health solutions;
statements regarding the seamless interaction of the digital health
solutions with Augmedix’s technology; statements regarding the
combination of technologies magnifying their impact and
tackling the full spectrum of administrative burdens that
clinicians face while improving clinician and patient experiences;
statements regarding Augmedix’s and Myndshft’s strategic steps to
streamline automated, end-to-end documentation; statements
regarding the automation of prior authorization submissions and
seamless scaling, integration, and support options; statements
regarding the expected partnerships allowing Augmedix to expand the
benefits of its platform by including prior authorization, clinical
decision support, and reduction in medical errors; statements
regarding the intent of Augmedix and Ellipsis to better serve
clinicians and patients in need of behavioral healthcare services;
statements regarding the ability of Augmedix and Ellipsis Health to
automate medical documentation, mental health screenings, SDOH
screenings, and topic analysis to help to identify issues earlier
and triage patients to the appropriate care; statements regarding
Augmedix’s plans to integrate the Ellipsis Health API into its
platform to enable clinicians to receive patients’ anxiety and
depression severity scores during clinical visits; statements
regarding the ability to offer high-quality, trusted solutions that
integrate medical documentation with a reduction in clinicians’
exposure to diagnosis-related errors; statements regarding The
Sullivan Group partnership sitting at the heart of helping to solve
the documentation burden, clinician burnout, and patient safety,
especially among emergency departments and ambulatory clinics;
statements regarding the expansion of the digital health solutions
within the Augmedix platform; statements regarding Augmedix
leveraging the wealth of structured data created by its platform to
further generate high-value services and substantial ROI; and
statements regarding the plan by the parties to enter into
definitive strategic partnership agreements and the expectation
that the parties will enter into definitive strategic partnership
agreements. Actual results could differ materially from those
stated or implied in forward-looking statements due to a number of
factors, including but not limited to, the ability of Augmedix and
the parties to enter into definitive agreements consistent with the
agreement in principle between the parties and the risks detailed
in our most recent Form 10-K filed with the U.S. Securities and
Exchange Commission on April 17, 2023, as well as other documents
that may be filed by us from time to time with the U.S. Securities
and Exchange Commission. The forward-looking statements included in
this press release represent our views as of the date of this press
release. We undertake no intention or obligation to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise. These forward-looking
statements should not be relied upon as representing our views as
of any date subsequent to the date of this press release.
Augmedix (NASDAQ:AUGX)
Gráfico Histórico do Ativo
De Out 2024 até Out 2024
Augmedix (NASDAQ:AUGX)
Gráfico Histórico do Ativo
De Out 2023 até Out 2024